Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to -$741000.0.

  • NovaBay Pharmaceuticals' Change in Accured Expenses fell 1193.35% to -$741000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $508000.0, marking a year-over-year increase of 23994.49%. This contributed to the annual value of -$195000.0 for FY2024, which is 8269.74% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$741000.0 for Q3 2025, which was down 1193.35% from -$779000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Change in Accured Expenses high stood at $1.7 million for Q1 2025, and its period low was -$1.5 million during Q3 2023.
  • Its 5-year average for Change in Accured Expenses is -$33684.2, with a median of $78000.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in NovaBay Pharmaceuticals' Change in Accured Expenses was 94814.81% (2025), while the steepest drop was 301600.0% (2025).
  • Over the past 5 years, NovaBay Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$425000.0 in 2021, then surged by 226.82% to $539000.0 in 2022, then tumbled by 69.94% to $162000.0 in 2023, then surged by 103.7% to $330000.0 in 2024, then tumbled by 324.55% to -$741000.0 in 2025.
  • Its Change in Accured Expenses was -$741000.0 in Q3 2025, compared to -$779000.0 in Q2 2025 and $1.7 million in Q1 2025.